Loading...
WBA logo

Walgreens Boots Alliance, Inc.NasdaqGS:WBA Rapporto sulle azioni

Cap. di mercato US$10.3b
Prezzo delle azioni
US$11.98
US$11.93
0.4% sopravvalutato sconto intrinseco
1Y27.7%
7D-1.8%
Valore del portafoglio
​
Vista

Walgreens Boots Alliance, Inc.

Report azionario NasdaqGS:WBA

Capitalizzazione di mercato: US$10.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Walgreens Boots Alliance (WBA) Panoramica del titolo

Walgreens Boots Alliance, Inc. opera come azienda sanitaria, farmaceutica e di vendita al dettaglio negli Stati Uniti, in Germania, nel Regno Unito e a livello internazionale. Maggiori dettagli

WBA analisi fondamentale
Punteggio fiocco di neve
Valutazione5/6
Crescita futura4/6
Prestazioni passate0/6
Salute finanziaria1/6
Dividendi0/6

Premi

Negoziato a 84.8% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 81.71% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili


WBA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Concorrenti di Walgreens Boots Alliance, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Walgreens Boots Alliance
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$11.98
Massimo di 52 settimaneUS$13.25
Minimo di 52 settimaneUS$8.08
Beta0.77
Variazione di 1 mese3.01%
Variazione a 3 mesi6.63%
Variazione di 1 anno27.72%
Variazione a 3 anni-65.83%
Variazione a 5 anni-67.77%
Variazione dall'IPO3,640.09%

Notizie e aggiornamenti recenti

Seeking Alpha • Jul 29

Walgreens Boots Alliance: Merger Arbitrage Opportunity

Summary Walgreens Boots Alliance is going private at $11.45/share plus up to $3 via a CVR, offering a potential $14.45 payout. The market is undervaluing the deal, ignoring both the turnaround momentum and the upside from the CVR, creating a merger arbitrage opportunity. Risks include regulatory approval and deal financing, but shareholder approval is secured and the buyer is known, making this a clean, short-term trade. WBA is a buy for merger arbitrage, capture the spread before the deal closes for a potential 25% return. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 29

Walgreens Boots Alliance: Merger Arbitrage Opportunity

Summary Walgreens Boots Alliance is going private at $11.45/share plus up to $3 via a CVR, offering a potential $14.45 payout. The market is undervaluing the deal, ignoring both the turnaround momentum and the upside from the CVR, creating a merger arbitrage opportunity. Risks include regulatory approval and deal financing, but shareholder approval is secured and the buyer is known, making this a clean, short-term trade. WBA is a buy for merger arbitrage, capture the spread before the deal closes for a potential 25% return. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Walgreens: Acquisition Is The Best-Case Scenario For The Company

Summary Walgreens Boots Alliance faces significant challenges, including rising inflation, heavy competition, and decreasing profitability, making it a Hold if the acquisition by Sycamore goes through. The company's financial health is concerning, with declining net income, negative free cash flow, and high debt levels, increasing the vulnerability to financial downturns. WBA's lack of its own Pharmacy Benefit Manager (PBM) puts it at a disadvantage compared to CVS, which owns Caremark and can better manage drug prices. If the acquisition proceeds, there's a potential 34.92% upside for shareholders; without it, WBA is overvalued, and I would rate it a Strong Sell. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

What To Do After Sycamore Partners Agrees To Buy Walgreens

Summary Sycamore Partners will acquire Walgreens Boots Alliance, Inc. for up to $23.7 billion, with WBA stock rising 7.3% to $11.38 post-announcement. Long-term investors may vote against the deal, seeking a better offer or supporting Walgreens' turnaround plan under CEO Tim Wentworth. Shareholders can hold WBA stock to receive a $3.00 Divested Asset Proceed Right, adding a 26% return on the current stock price. Investors may also consider other four other consumer staples or drug retail stocks. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Walgreens Boots Alliance: Larger Structural Problems Remain

Summary Walgreens-Boots Alliance faces severe structural issues, including margin compression, falling earnings, and weak balance sheet despite recent dividend cuts. The company is struggling with increased competition, labor shortages, and online retail pressures, leading to store closures and failed healthcare expansion. Significant uncertainties surround pending litigation and regulatory actions, with potential financial risks from opioid-related lawsuits and PBM practices. WBA remains overvalued compared to industry averages, lacking a viable plan to address core issues, making it a strong sell recommendation. Read the full article on Seeking Alpha
Seeking Alpha • Feb 03

Walgreens: Don't Expect The Dividend To Come Back Anytime Soon

Summary Walgreens Boots Alliance's dividend cut was necessary, in my view, given the challenged free cash flow, debt maturities, and mounting legal liabilities. WBA will likely generate only about $100-200 million of attributable cash in FY2026. The Footprint Optimization Plan aims to cut costs but also risks becoming a financial burden, with $2.2 billion in projected charges. Legal liabilities, particularly opioid litigation, threaten WBA's financial stability. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Walgreens Could Have Reached Its Bottom, But Caution Is Still Advised

Summary Walgreens Boots Alliance has seen a significant decline in stock price, with my position down 75%, leading me to reaffirm my "Hold" rating. WBA's dividend yield is 10.5%, but sustainability is questionable due to negative free cash flow and significant debt levels. Walgreens' recent financial results show increasing sales but worsening operating losses and net losses, with future growth expectations being modest. Despite the low stock price suggesting undervaluation, Walgreens' profitability struggles and potential dividend cuts make it a risky investment. Read the full article on Seeking Alpha
Seeking Alpha • Dec 20

Walgreens' Rally Sputters Amid Takeover Chatter (Rating Downgrade)

Summary I am downgrading Walgreens Boots Alliance from a buy to a hold due to balanced risks and less compelling valuation. Despite a 10% gain since my September buy call, new fundamental developments and tepid M&A trends warrant a cautious stance. WBA's Q4 results beat expectations, but a soft FY 2025 guide, store closures, and ongoing sales pressures pose significant risks. Technically, WBA faces resistance at $11, with a trading range likely between $8-$11, making the stock less attractive. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

How Investors Should Assess The Potential Walgreens Buyout

Summary Walgreens surged 18% amid buyout rumors with Sycamore Partners, but the rally may be short-lived as markets cast doubt on the deal's feasibility. History: Walgreens' market cap plummeted from $100 billion in 2015 to $8.44 billion, with recent struggles including a write-down on VillageMD. Sycamore Partners may need partners for the acquisition, reducing deal likelihood; Walgreens could pursue internal plans to improve operations. Despite poor profitability and growth, Walgreens offers an attractive valuation and high yield, maintaining a 'hold' rating from Seeking Alpha Quant. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Walgreens: 11.9% Dividend Yield Still On Unsteady Legs

Summary Walgreens faces ongoing financial challenges, including a potential future dividend cut, despite recent progress in cost-cutting and debt reduction. The company's 11.9% dividend yield is not covered by free cash flow, with legal fees and operational costs impacting cash flow sustainability. Management's turnaround efforts, including store closures and asset monetization, show promise but will take years to fully materialize. Investors should be cautious of the attractive yield, as the high likelihood of additional dividend cuts makes Walgreens a risky investment. Read the full article on Seeking Alpha
Seeking Alpha • Oct 29

Walgreens Q4: 2 Signs Of A Dividend Trap

Summary Walgreens Boots Alliance’s forward yield hovers around 10.8%, the highest among the S&P 500 index. Such yield raises concerns about a potential dividend trap due to bleak growth prospects and financial struggles, as reported in its recent Q4 earnings. Its Q4 earnings reveal significant challenges, including store closures and a bleak EPS growth outlook. Despite cost-cutting and divestiture efforts, WBA's heavy debt burden and declining cash flow may threaten dividend safety in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Oct 23

Walgreens: Undervalued Pharma Giant Poised For A Turnaround Amid Cost-Cutting And Activist Investor Potential

Summary Walgreens Boots Alliance is significantly undervalued, trading at low P/E multiples and a 44% discount to its book value, with strong upside potential. New CEO Tim Wentworth's cost-cutting strategy and potential sale of VillageMD are expected to boost cash flow and equity value. Conservative valuation models (DCF, trading comps, exit multiple, GGM) indicate WBA is worth at least $28 per share, making it a strong buy. Risks include new management execution and competition from Walmart's pharmacy arm, but WBA's market share and cost-cutting plans provide a margin of safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 15

Walgreens: A Turnaround Stock To Avoid

Summary Walgreens plans to close 1,200 stores, impacting 13.79% of its total locations, to restructure and improve financial health. Despite beating Wall Street estimates, Walgreens' adjusted operating income fell 38%, and adjusted EPS dropped to $0.39 from $0.67 a year ago. The company's financials have been weak, with negative free cash flow and inconsistent performance, making it a risky investment. Walgreens needs to downsize stores significantly, focusing more on pharmacy operations, to survive long-term and improve profitability. Read the full article on Seeking Alpha
Seeking Alpha • Sep 29

Walgreens Stock: Cheap At 3x FWD P/E, But Still Not Worth Buying

Summary Walgreens is at risk of another dividend cut, as its free cash flow doesn't cover the current dividend payment, nor is it expected to in the next year. Walgreens faces intense competition, as other companies can offer the same products at a cheaper price. The company's low cash position relative to its debt is another reason why the dividend is at risk. The low P/E ratio is justified, given the company's current issues and the fact that EPS estimates may get revised lower, as they have in the recent past. Further, its price/FCF ratio is not nearly as attractive. Read the full article on Seeking Alpha
Seeking Alpha • Sep 06

Walgreens: Short Interest Surge Indicates It's Time To Cut Your Losses

Summary This article focuses on two new headwinds that recently developed for Walgreens Boots Alliance. The first one is a surge in its short interest to the 10%+ level, which could have negative feedback on its financials. The second one is the increased rollouts of direct-to-consumer pharmaceutical channels, which could further squeeze WBA’s margin space. The stock's valuation is extremely low in P/E (of ~3x), but its heavy debt makes it less attractive in EV terms. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Is Walgreens Ready To Rebound?

Summary Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments. Walgreens' partnership with Instacart to accept SNAP/EBT payments online at over 7,500 stores could potentially generate $200 million in annual sales, broadening its customer base. Walgreens reported a 37% YoY drop in adjusted EPS to $0.63 but highlighted $1 billion in targeted cost savings, potentially adding $400 million to operating income. Read the full article on Seeking Alpha
Seeking Alpha • Aug 13

Walgreens Boots Alliance: Likely A Value Trap, But Could Be A Speculative Long-Term Play

Summary Walgreens Boots Alliance, Inc. is a well-known pharmacy chain operating in the U.S., U.K., Germany, and internationally. Our previous investment thesis based on dividend discount model failed as WBA's stock declined by 70% despite attractive valuation results. The updated dividend discount model shows the stock is still undervalued, but risks, including dividend safety, debt, and market sentiment, make it a "hold". Read the full article on Seeking Alpha
Seeking Alpha • Aug 02

Walgreens: A Painful Turnaround Lesson

Summary As my worst investment in over 20 years, Walgreens Boots Alliance, Inc. stock served me a painful lesson about turnaround. Turnaround requires fundamentally sound business economics and plenty of financial resources. I misjudged Walgreens Boots Alliance's business economics badly. Recent developments also lead me to question if it has the financial resources to support a potential turnaround. Read the full article on Seeking Alpha
Seeking Alpha • Jul 09

Walgreens: Here's What Comes Next

Summary WBA stock drops 57% YTD, hitting 27-year lows, amid disappointing Q3 results and profit outlook cuts. Challenging environment with weak consumer spending and inflation pressures are impacting Walgreens' performance. Despite facing cash flow crisis and restructuring, WBA posts 2.6% sales growth driven by robust healthcare segment performance. Potential for rebound with aggressive cost-cutting and strategic shift to healthcare. By year-end, stock price targets range from $8.25 to $23.35, supported by volume price trends and RSI indicators. Read the full article on Seeking Alpha
Seeking Alpha • Jul 02

Walgreens: Yielding Over 8% Following The Earnings Drop

Summary Walgreens stock plummeted 56% in 2024, and is now trading below $12 a share. Quarterly dividend now yields 8%+, providing a potential opportunity for robust passive income. Challenges in the operating environment require new approach, potential store closures and divestitures in the future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Walgreens: Beware The Value Trap Ahead Of Earnings

Summary Walgreens Boots Alliance shares have cratered following the stock being removed from the Dow Jones Industrial Average. While Q2 2024 adjusted operating EPS beat expectations, its management team was not all that optimistic about the rest of the year. Shares are expected to be volatile after this week's earnings release. I highlight key price levels to monitor along with putting forward a valuation assessment. Read the full article on Seeking Alpha
Seeking Alpha • May 30

Walgreens: Another Dividend Cut Could Be Coming Soon (Rating Downgrade)

Summary Walgreens has faced headwinds and cut its dividend by nearly 50% earlier this year. The company's recent earnings showed some positive signs, but headwinds persist, which could lead to an additional dividend cut by the end of the year. The dividend coverage is a concern as operating cash flow and free cash flow were negative in the first half of the year. Their P/E of less than 5x is the lowest level seen since 1998, giving WBA an attractive dividend yield over 9%. Read the full article on Seeking Alpha
Seeking Alpha • May 22

5 Reasons Walgreens Fell By 6.4% To Nearly 25-Year Lows

Summary Walgreens Boots Alliance stock declined by 6.4% to a 25-year low of $16.68, a price not seen since 1998. Short interest, potential dividend cuts, and lingering ex-CEO worries are among reasons for the decline. Walgreens value grades compared to the sector discussed and compared to that of Humana, Cigna, CVS Health, and more. Read the full article on Seeking Alpha

Rendimenti per gli azionisti

WBAUS Consumer RetailingUS Mercato
7D-1.8%-0.9%2.1%
1Y27.7%19.7%30.6%

Ritorno vs Industria: WBA ha superato il US Consumer Retailing che ha restituito 19.7 % nell'ultimo anno.

Rendimento vs Mercato: WBA ha superato il mercato US che ha restituito 30.6 % nell'ultimo anno.

Volatilità dei prezzi

Is WBA's price volatile compared to industry and market?
WBA volatility
WBA Average Weekly Movement1.0%
Consumer Retailing Industry Average Movement5.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: WBA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di WBA è diminuita da 8% a 1% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
1909252,500Tim Wentworthwww.walgreensbootsalliance.com

Walgreens Boots Alliance, Inc. opera nel settore sanitario, farmaceutico e della vendita al dettaglio negli Stati Uniti, in Germania, nel Regno Unito e a livello internazionale. Opera attraverso tre segmenti: U.S. Retail Pharmacy, International e U.S.

Walgreens Boots Alliance, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Walgreens Boots Alliance con la sua capitalizzazione di mercato?
WBA statistiche fondamentali
Capitalizzazione di mercatoUS$10.32b
Utili (TTM)-US$6.30b
Ricavi(TTM)US$154.58b
0.1x
Rapporto P/S
-1.6x
Rapporto P/E

WBA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
WBA Conto economico (TTM)
RicaviUS$154.58b
Costo del fatturatoUS$128.11b
Profitto lordoUS$26.47b
Altre speseUS$32.77b
Utili-US$6.30b

Ultimi utili riportati

May 31, 2025

Prossima data di guadagno

n/a

Utile per azione (EPS)-7.28
Margine lordo17.13%
Margine di profitto netto-4.07%
Rapporto debito/patrimonio netto100.7%

Come si è comportato WBA nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/08/27 00:18
Prezzo dell'azione a fine giornata2025/08/27 00:00
Utili2025/05/31
Utili annuali2024/08/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Walgreens Boots Alliance, Inc. è coperta da 23 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Christopher GrajaArgus Research Company
Eric ColdwellBaird
Charley JonesBarrington Research Associates, Inc.